Deep Fission Nuclear Completes $30M Financing in a Go-Public Transaction
8.9.2025 13:00:00 CEST | Business Wire | Press Release
Deep Fission, Inc. (“Deep Fission” or the “Company”), a pioneering advanced nuclear energy company placing small modular pressurized water reactors in boreholes one mile underground, announced today it raised $30M in a heavily oversubscribed private placement offering at $3.00 per share as well as completed a go-public reverse merger transaction with Surfside Acquisition Inc., which has been renamed Deep Fission, Inc.
The Department of Energy (DOE) recently announced that Deep Fission was selected to participate in President Trump’s Nuclear Reactor Pilot Program. The initiative provides an opportunity to streamline a pilot reactor, targeting criticality by July 4, 2026, with expected rapid commercialization to follow.
“This is a unique moment for the nuclear industry,” said Liz Muller, Co-Founder and Chief Executive Officer of Deep Fission. “Deep Fission has the right technology, at the right time, and in the right place. With this funding, we can begin building our pilot reactor, with the goal of completion in 2026. We believe we can scale our technology rapidly and profitably to address the massive energy demand from AI data centers and other customers around the world.”
Deep Fission’s proprietary design combines proven methods from the nuclear, oil and gas, and geothermal industries, while utilizing off-the-shelf parts and readily available, low-enriched uranium (LEU) to simplify supply chains. By siting the reactor one mile underground, the surrounding geology offers natural shielding and protection with billions of tons of bedrock providing passive safety and containment. The approach reduces the surface footprint, strengthens security, and is designed to enable a faster, more affordable path to deployment. The Company is targeting a levelized cost of electricity (LCOE) of 5-7 cents per kWh from its first-of-a-kind commercial implementation.
Backed by a robust intellectual property portfolio, the Company currently has 24 pending patent applications with 1 US application allowed and over 40 unique innovations.
As a result of the reverse merger, the Company is now subject to the public reporting requirements of the Securities Exchange Act of 1934, as amended. The Company intends to file a resale registration statement on Form S-1 with the SEC to register its outstanding shares and will apply to have its shares approved for quotation on the OTCQB (The Venture Market).
The Benchmark Company, LLC, Seaport Global Securities LLC, Network 1 Financial Securities, Inc., Phoenix Financial Services, and Dinosaur Financial Group, LLC served as placement agents. Montrose Capital Partners sponsored the go-public transaction, and investors in Deep Fission include 8VC, Deep Future, Wave Function, Ed Eisler of EE Holdings, and Mark Tompkins of Montrose Capital Partners.
About Deep Fission
Deep Fission is revolutionizing the energy landscape with innovative technology that places a small modular pressurized water reactor in a borehole one mile underground. Founded and led by a team of seasoned scientists, engineers, and entrepreneurs, the Company is committed to delivering safe, reliable, and affordable low-carbon power at scale. Deep Fission was recently selected for the Department of Energy’s new Reactor Pilot Program and is targeting criticality by July 2026. Deep Fission was founded in 2023 by father-daughter team Elizabeth and Richard Muller. Learn more at deepfission.com.
For media inquiries, please contact:
chloe.frader@deepfission.com
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to, among others, our plans, objectives and expectations for our business, future growth, awards, backlog, operations and financial performance and condition. Forward-looking statements can include terminology such as “may,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “will,” “could,” “project,” “target,” “potential,” “continue” and similar expressions that do not relate solely to historical matters or actual results. Such forward-looking statements include statements regarding the company’s: intent to file a resale registration statement on Form S-1 and apply for quotation on the OTCQB; target of an LCOE of 5-7 cents per kWh; plans to streamline a pilot reactor by July 4, 2026 in connection with the DOE’s Reactor Pilot Program and projections of initial reactor build costs. Forward-looking statements are based on management’s belief and assumptions, including current expectations and projections about future events and trends, and on information currently available to management.
Forward-looking statements in this or any other release are subject to a number of risks, uncertainties, and assumptions that could cause actual results to be materially different from those forecasted assumed. Such risks, uncertainties, and assumptions are subject to a number of factors, including, among others: that the Company’s initial pilot facility and commercial applications may progress more slowly than projected or encounter delays and engineering changes that increase the expense and capital requirements for execution; that the market for our Deep Fission Reactor technology is not yet established and may not achieve the growth potential we expect or may grow more slowly than expected; that the necessary approvals and licenses relating to various aspects of our business may not be granted on a timely basis, if at all; that the cost of electricity generated from our Deep Fission Reactors may not be cost competitive with future electricity generation sources in some markets; that we may not succeed in entering into any binding contract with any customer to deliver our Deep Fission Reactors; that we may not be successful in entering into partnerships with strategic partners and government entities that would be important to our business; that we have limited experience commercializing our products at a large scale; that our SDA applications may not be approved, and any rework necessary to address NRC concerns could significantly delay the commercialization of our products; potentially having to defend ourselves against intellectual property infringement claims; the possibility that the benefits to customers of our products could be supplanted by other technologies or solutions or competitors’ products; that our auditor has issued a “going concern” opinion; that our business plans require a significant amount of capital but that there can be no assurance that such capital will be available to us on a timely basis, if at all. The foregoing is not an exhaustive list of all the factors that may cause any forward-looking statements to prove inaccurate or our actual results may differ materially from our expectations and forecasts. Moreover, we operate in a highly regulated environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this Release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. We cannot guarantee future results, performance, or achievements. We undertake no obligation to update any forward-looking statements for any reason after the date of this Release or to conform these statements to actual results or revised expectations, except as required by law.
Additional information concerning the factors above and other factors will be found in the Company’s public filings with the SEC, including the sections titled “Forward-Looking Statements” and “Risk Factors” in the Company’s Current Report on Form 8-K that will be filed with the SEC on or about September 11, 2025 and in subsequent filings with the SEC. The referenced SEC filings will be available either publicly when filed or upon request.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250908384960/en/
Contacts
IR@deepfission.com
707-400-0778
For media inquiries, please contact:
chloe.frader@deepfission.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom